Cerclage, progesterone and α-hydroxyprogeterone caproate treatment in women at risk for preterm delivery

References

• Norwitz ER, Caughey AB. Progesterone supplementation and the prevention of preterm birth. Rev Obstet Gynecol 2011;4:60–72
   PubMedGoogle Scholar
• Khandelwal M. Vaginal progesterone in risk reduction of preterm birth in women with short cervix in the midtrimester of pregnancy. Int J Womens Health 2012;4:481–90
   PubMedGoogle Scholar
• Goldenberg RL, Culhane JF, Iams JD, et al. Epidemiology and causes of preterm birth. Lancet 2008;371:75–84
   PubMed Web of Science ®Google Scholar
• Campbell S. Universal cervical-length screening and vaginal progesterone prevents early preterm births, reduces neonatal morbidity and is cost saving: doing nothing is no longer an option. Ultrasound Obstet Gynecol 2011;38:1–9
   PubMed Web of Science ®Google Scholar
• Ward RM, Beachy JC. Neonatal complications following preterm birth. BJOG 2003;110:8–16
   PubMed Web of Science ®Google Scholar
• Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 2006:CD004454
   PubMed Web of Science ®Google Scholar
• To MS, Alfirevic Z, Heath VC, et al. Cervical cerclage for prevention of preterm delivery in women with short cervix: randomised controlled trial. Lancet 2004;363:1849–53
   PubMed Web of Science ®Google Scholar
• Di Renzo GC, Roura LC, Facchinetti F, et al. Guidelines for the management of spontaneous preterm labor: identification of spontaneous preterm labor, diagnosis of preterm premature rupture of membranes, and preventive tools for preterm birth. J Matern Fetal Neonatal Med 2011;24:659–67
   PubMed Web of Science ®Google Scholar
• Neilson JP. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Obstet Gynecol 2007;109:189–90
   PubMed Web of Science ®Google Scholar
• Roberts D. Antenatal corticosteroids to reduce neonatal morbidity and mortality. Green-top Guideline No. 7. Liverpool: Royal College of Obstetricians and Gynaecologists; 2010
   Google Scholar
• Simchen MJ, Alkazaleh F, Adamson SL, et al. The fetal cardiovascular response to antenatal steroids in severe early-onset intrauterine growth restriction. Am J Obstet Gynecol 2004;190:296–304
   PubMed Web of Science ®Google Scholar
• Halliday HL. Use of steroids in the perinatal period. Paediatr Respir Rev 2004;5:S321–7
   PubMedGoogle Scholar
• Stutchfield P, Whitaker R, Russell I. Antenatal betamethasone and incidence of neonatal respiratory distress after elective caesarean section: pragmatic randomised trial. BMJ 2005;331:662
   PubMed Web of Science ®Google Scholar
• Dalziel SR, Lim VK, Lambert A, et al. Antenatal exposure to betamethasone: psychological functioning and health related quality of life 31 years after inclusion in randomised controlled trial. BMJ 2005;331:665
   PubMed Web of Science ®Google Scholar
• Berghella V, Rafael TJ, Szychowski JM, et al. Cerclage for short cervix on ultrasonography in women with singleton gestations and previous preterm birth: a meta-analysis. Obstet Gynecol 2011;117:663–71
   PubMed Web of Science ®Google Scholar
• Romero R, Yeo L, Miranda J, et al. A blueprint for the prevention of preterm birth: vaginal progesterone in women with a short cervix. J Perinat Med 2013;41:27–44
   PubMed Web of Science ®Google Scholar
• Facchinetti F, Paganelli S, Comitini G, et al. Cervical length changes during preterm cervical ripening: effects of 17-alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol 2007;196:453–4
   PubMed Web of Science ®Google Scholar
• Johnson JW, Austin KL, Jones GS, et al. Efficacy of 17alpha-hydroxyprogesterone caproate in the prevention of premature labor. N Engl J Med 1975;293:675–80
   PubMed Web of Science ®Google Scholar
• Fonseca EB, Celik E, Parra M, et al. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med 2007;357:462–9
   PubMed Web of Science ®Google Scholar
• Progesterone and preterm birth prevention: translating clinical trials data into clinical practice. Am J Obstet Gynecol 2012; 206:376–86
   Google Scholar
• Hassan SS, Romero R, Vidyadhari D, et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2011;38:18–31
   PubMed Web of Science ®Google Scholar
• Romero R, Nicolaides K, Conde-Agudelo A, et al. Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual patient data. Am J Obstet Gynecol 2012;206:124–19
   PubMed Web of Science ®Google Scholar
• Dodd JM, Jones L, Flenady V, et al. Prenatal administration of progesterone for preventing preterm birth in women considered to be at risk of preterm birth. Cochrane Database Syst Rev 2013;7:CD004947
   PubMed Web of Science ®Google Scholar
• Grobman WA, Thom EA, Spong CY, et al. 17 alpha-hydroxyprogesterone caproate to prevent prematurity in nulliparas with cervical length less than 30 mm. Am J Obstet Gynecol 2012;207:390–8
   PubMed Web of Science ®Google Scholar
• Keeler SM, Kiefer D, Rochon M, et al. A randomized trial of cerclage versus 17 alpha-hydroxyprogesterone caproate for treatment of short cervix. J Perinat Med 2009;37:473–9
   PubMed Web of Science ®Google Scholar
• Conde-Agudelo A, Romero R, Nicolaides K, et al. Vaginal progesterone versus cervical cerclage for the prevention of preterm birth in women with a sonographic short cervix, previous preterm birth, and singleton gestation: a systematic review and indirect comparison metaanalysis. Am J Obstet Gynecol 2013;208:42.e1–e18
   Web of Science ®Google Scholar
• Berghella V, Figueroa D, Szychowski JM, et al. 17-alpha-hydroxyprogesterone caproate for the prevention of preterm birth in women with prior preterm birth and a short cervical length. Am J Obstet Gynecol 2010;202:351–6
   PubMed Web of Science ®Google Scholar
• O'Brien JM, Adair CD, Lewis DF, et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2007;30:687–96
   PubMed Web of Science ®Google Scholar
• O'Brien JM, Defranco EA, Adair CD, et al. Effect of progesterone on cervical shortening in women at risk for preterm birth: secondary analysis from a multinational, randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 2009;34:653–9
   PubMed Web of Science ®Google Scholar
• Rode L, Langhoff-Roos J, Andersson C, et al. Systematic review of progesterone for the prevention of preterm birth in singleton pregnancies. Acta Obstet Gynecol Scand 2009;88:1180–9
   PubMed Web of Science ®Google Scholar
• Meis PJ, Klebanoff M, Thom E, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003;348:2379–85
   PubMed Web of Science ®Google Scholar
• Spong CY, Meis PJ, Thom EA, et al. Progesterone for prevention of recurrent preterm birth: impact of gestational age at previous delivery. Am J Obstet Gynecol 2005;193:1127–31
   PubMed Web of Science ®Google Scholar
• ACOG Committee Opinion number 419 October 2008 (replaces no. 291, November 2003). Use of progesterone to reduce preterm birth. Obstet Gynecol 2008;112:963–5
   Google Scholar
• Keirse MJ. Progesterone and preterm: seventy years of “deja vu” or “still to be seen”? Birth 2004;31:230–5
   PubMed Web of Science ®Google Scholar
• Northen AT, Norman GS, Anderson K, et al. Follow-up of children exposed in utero to 17 alpha-hydroxyprogesterone caproate compared with placebo. Obstet Gynecol 2007;110:865–72
   PubMed Web of Science ®Google Scholar
• Chanrachakul B, Broughton PF, Warren AY, et al. Progesterone enhances the tocolytic effect of ritodrine in isolated pregnant human myometrium. Am J Obstet Gynecol 2005;192:458–63
   PubMed Web of Science ®Google Scholar
• da Fonseca EB, Bittar RE, Carvalho MH, et al. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2003;188:419–24
   PubMed Web of Science ®Google Scholar
• Bomba-Opon DA, Kosinska-Kaczynska K, Kosinski P, et al. Vaginal progesterone after tocolytic therapy in threatened preterm labor. J Matern Fetal Neonatal Med 2012;25:1156–9
   PubMed Web of Science ®Google Scholar
• Borna S, Sahabi N. Progesterone for maintenance tocolytic therapy after threatened preterm labour: a randomised controlled trial. Aust N Z J Obstet Gynaecol 2008;48:58–63
   PubMed Web of Science ®Google Scholar
• Grobman WA, Gilbert SA, Iams JD, et al. Activity restriction among women with a short cervix. Obstet Gynecol 2013;121:1181–6
   PubMed Web of Science ®Google Scholar
• Lim AC, Schuit E, Bloemenkamp K, et al. 17alpha-hydroxyprogesterone caproate for the prevention of adverse neonatal outcome in multiple pregnancies: a randomized controlled trial. Obstet Gynecol 2011;118:513–20
   PubMed Web of Science ®Google Scholar
• da Fonseca EB, Bittar RE, Carvalho MH, et al. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2003;188:419–24
   PubMed Web of Science ®Google Scholar
• Papernik-Berkauer F. Etyde en double aveugle d'un medicament prevenant la survenue prematuree de l'accouchement premature. Edition Schering 1970;Seried IV, volume 3:65–8
   Google Scholar
• Rai P, Rajaram S, Goel N, et al. Oral micronized progesterone for prevention of preterm birth. Int J Gynaecol Obstet 2009;104:40–3
   PubMed Web of Science ®Google Scholar